Stanford
Foresight Diagnostics Raises $12.5M in Series A to Commercialize MRD Detection Tech
The company, founded by Stanford University scientists, is advancing a technology called PhasED-Seq for cancer minimal residual disease detection.
Amazon to Give Out $12M Under Next Phase of AWS Diagnostics Development Initiative
The company is planning to fund projects for SARS-CoV-2 testing, early disease detection, disease prognostics, and public health genomics projects.
Fluidigm CEO Chris Linthwaite said the company aims to further penetrate the diagnostic and clinical markets with both its microfluidics and mass cytometry businesses.
The RT-LAMP-based platform, which the researchers plan to commercialize through a spinout company, could be adapted for other infectious disease tests.
Later this year, the inherited cardiovascular disease clinic also plans to implement a preventive genomics program with polygenic risk score and PGx testing.